{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:04:30Z","timestamp":1789902270800,"version":"4.0.1"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.phrs.2026.108449","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:40:47Z","timestamp":1789054847000},"page":"108449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Metal-based epigenetic therapeutics in cancer: Mechanisms, targets, and opportunities for overcoming drug resistance"],"prefix":"10.1016","volume":"232","author":[{"given":"Julia","family":"Astapczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga Klaudia","family":"Szewczyk-Roszczenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yegor","family":"Vassetzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7148-6111","authenticated-orcid":false,"given":"Robert","family":"Czarnomysy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.phrs.2026.108449_bib1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3923\/ajbs.2025.516.532","article-title":"Epigenetic modifications in cancer etiology, diagnosis and therapy","volume":"18","author":"Tajudeen","year":"2025","journal-title":"Asian J. Biol. Sci."},{"key":"10.1016\/j.phrs.2026.108449_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejim.2023.05.036","article-title":"How epigenetics impacts on human diseases","volume":"114","author":"Farsetti","year":"2023","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.phrs.2026.108449_bib3","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.toxrep.2022.03.037","article-title":"Epigenetic mechanisms in metal carcinogenesis","volume":"9","author":"Mani\u0107","year":"2022","journal-title":"Toxicol. Rep."},{"issue":"4173","key":"10.1016\/j.phrs.2026.108449_bib4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1126\/science.187.4173.226","article-title":"DNA modification mechanisms and gene activity during development","volume":"187","author":"Holliday","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108449_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s42255-026-01495-y","article-title":"Epigenetic adaptation of beta cells across lifespan and disease","author":"Manduchi","year":"2026","journal-title":"Nat. Metab."},{"issue":"7827","key":"10.1016\/j.phrs.2026.108449_bib6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41586-020-2747-1","article-title":"Structure of nucleosome-bound DNA methyltransferases DNMT3A and DNMT3B","volume":"586","author":"Xu","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.phrs.2026.108449_bib7","doi-asserted-by":"crossref","first-page":"6874","DOI":"10.1038\/s41598-023-33932-3","article-title":"The genome-wide mutational consequences of DNA hypomethylation","volume":"13","author":"Besselink","year":"2023","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.phrs.2026.108449_bib8","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of Histone Acetylation: The Histone Deacetylase Enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.phrs.2026.108449_bib9","first-page":"253","article-title":"Epigenetic Therapies in MDS and AML","volume":"754","author":"Griffiths","year":"2013"},{"issue":"1\u20132","key":"10.1016\/j.phrs.2026.108449_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1615\/CritRevOncog.2015012997","article-title":"Histone Deacetylases and Mechanisms of Regulation of Gene Expression","volume":"20","author":"Chen","year":"2015","journal-title":"Crit. Rev. Oncog."},{"issue":"3","key":"10.1016\/j.phrs.2026.108449_bib11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nchembio.313","article-title":"Chemical phylogenetics of histone deacetylases","volume":"6","author":"Bradner","year":"2010","journal-title":"Nat. Chem. Biol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108449_bib12","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41594-019-0298-7","article-title":"Histone lysine methyltransferases in biology and disease","volume":"26","author":"Husmann","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108449_bib13","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.phrs.2026.108449_bib14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/gb-2005-6-8-227","article-title":"The SET-domain protein superfamily: protein lysine methyltransferases","volume":"6","author":"Dillon","year":"2005","journal-title":"Genome Biol."},{"issue":"21","key":"10.1016\/j.phrs.2026.108449_bib15","doi-asserted-by":"crossref","first-page":"6699","DOI":"10.1021\/jacs.6b01612","article-title":"Nucleosome Binding Alters the Substrate Bonding Environment of Histone H3 Lysine 36 Methyltransferase NSD2","volume":"138","author":"Poulin","year":"2016","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.phrs.2026.108449_bib16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1471-2164-11-92","article-title":"Identification of arginine- and lysine-methylation in the proteome of Saccharomyces cerevisiae and its functional implications","volume":"11","author":"Pang","year":"2010","journal-title":"BMC Genom."},{"issue":"5","key":"10.1016\/j.phrs.2026.108449_bib17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4161\/epi.24547","article-title":"Large-scale global identification of protein lysine methylation in vivo","volume":"8","author":"Cao","year":"2013","journal-title":"Epigenetics"},{"issue":"1","key":"10.1016\/j.phrs.2026.108449_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10555-025-10253-7","article-title":"Epigenetic drugs in cancer therapy","volume":"44","author":"Suraweera","year":"2025","journal-title":"Cancer Metastas-.-. Rev."},{"key":"10.1016\/j.phrs.2026.108449_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00080","article-title":"DNA Methyltransferases: a novel target for prevention and therapy","volume":"4","author":"Subramaniam","year":"2014","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108449_bib20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1146\/annurev-med-111314-035900","article-title":"Epigenetic therapeutics: a new weapon in the war against cancer","volume":"67","author":"Ahuja","year":"2016","journal-title":"Annu. Rev. Med."},{"issue":"11","key":"10.1016\/j.phrs.2026.108449_bib21","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3390\/genes11111336","article-title":"DNMTs and Impact of CpG Content, Transcription Factors, Consensus Motifs, lncRNAs, and Histone Marks on DNA Methylation","volume":"11","author":"Loaeza-Loaeza","year":"2020","journal-title":"Genes"},{"issue":"11","key":"10.1016\/j.phrs.2026.108449_bib22","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.biochi.2012.07.025","article-title":"DNA methylation inhibitors in cancer: Recent and future approaches","volume":"94","author":"Gros","year":"2012","journal-title":"Biochimie"},{"key":"10.1016\/j.phrs.2026.108449_bib23","doi-asserted-by":"crossref","first-page":"10903","DOI":"10.2147\/OTT.S217767","article-title":"DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses","volume":"12","author":"Dan","year":"2019","journal-title":"OncoTargets Ther."},{"issue":"1","key":"10.1016\/j.phrs.2026.108449_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/biom7010003","article-title":"DNA Methylation Targeting: The DNMT\/HMT Crosstalk Challenge","volume":"7","author":"Castillo-Aguilera","year":"2017","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.phrs.2026.108449_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.pharmthera.2014.04.004","article-title":"Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights","volume":"143","author":"Bose","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"44","key":"10.1016\/j.phrs.2026.108449_bib26","doi-asserted-by":"crossref","first-page":"77254","DOI":"10.18632\/oncotarget.20460","article-title":"Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines","volume":"8","author":"Bernhart","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.phrs.2026.108449_bib27","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1586\/era.10.88","article-title":"Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors","volume":"10","author":"Grant","year":"2010","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2026.108449_bib28","doi-asserted-by":"crossref","first-page":"9801","DOI":"10.1038\/s41467-024-52528-7","article-title":"Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial","volume":"15","author":"Baretti","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.phrs.2026.108449_bib29","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0955-0674(00)00096-X","article-title":"Acetylation and chromosomal functions","volume":"12","author":"Cheung","year":"2000","journal-title":"Curr. Opin. Cell. Biol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108449_bib30","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1021\/acs.jmedchem.8b02008","article-title":"Discovery of a novel chemotype of histone lysine methyltransferase EHMT1\/2 (GLP\/G9a) inhibitors: rational design, synthesis, biological evaluation, and co-crystal structure","volume":"62","author":"Milite","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108449_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-69708-2","article-title":"Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI\/SNF alterations: a phase II basket study","author":"Gounder","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.108449_bib32","article-title":"UNC0638, a G9a inhibitor, suppresses epithelial\u2011mesenchymal transition\u2011mediated cellular migration and invasion in triple negative breast cancer","author":"Liu","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.phrs.2026.108449_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118054","article-title":"Tranylcypromine-derived LSD1 inhibitors: Synthetic strategies, structure-activity relationships, and anticancer potential","volume":"299","author":"Sheikh","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2026.108449_bib34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13148-025-02010-y","article-title":"Lysine demethylases 6 A and 6B as epigenetic regulators in therapeutic resistance of cancer","volume":"17","author":"Yang","year":"2025","journal-title":"Clin. Epigenetics"},{"issue":"7327","key":"10.1016\/j.phrs.2026.108449_bib35","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.phrs.2026.108449_bib36","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1110\/ps.037580.108","article-title":"Solution structure of the extraterminal domain of the bromodomain-containing protein BRD4","volume":"17","author":"Lin","year":"2008","journal-title":"Protein Sci."},{"issue":"13","key":"10.1016\/j.phrs.2026.108449_bib37","doi-asserted-by":"crossref","first-page":"9304","DOI":"10.1074\/jbc.M113.523019","article-title":"Affinity Map of Bromodomain Protein 4 (BRD4) Interactions with the Histone H4 Tail and the Small Molecule Inhibitor JQ1","volume":"289","author":"Jung","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.phrs.2026.108449_bib38","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/S0002-9440(10)63049-0","article-title":"BRD4 Bromodomain Gene Rearrangement in Aggressive Carcinoma with Translocation t(15;19)","volume":"159","author":"French","year":"2001","journal-title":"Am. J. Pathol."},{"issue":"15","key":"10.1016\/j.phrs.2026.108449_bib39","doi-asserted-by":"crossref","first-page":"eade3422","DOI":"10.1126\/sciadv.ade3422","article-title":"Targeting BRD3 eradicates nuclear TYRO3-induced colorectal cancer metastasis","volume":"9","author":"Hsu","year":"2023","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.phrs.2026.108449_bib40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molcel.2008.01.018","article-title":"The Double Bromodomain Proteins Brd2 and Brd3 Couple Histone Acetylation to Transcription","volume":"30","author":"LeRoy","year":"2008","journal-title":"Mol. Cell."},{"issue":"7","key":"10.1016\/j.phrs.2026.108449_bib41","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/jcmm.13059","article-title":"The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo","volume":"21","author":"Jostes","year":"2017","journal-title":"J. Cell. Mol. Med."},{"issue":"2","key":"10.1016\/j.phrs.2026.108449_bib42","doi-asserted-by":"crossref","first-page":"pkz093","DOI":"10.1093\/jncics\/pkz093","article-title":"Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors","volume":"4","author":"Piha-Paul","year":"2020","journal-title":"JNCI Cancer Spectr."},{"issue":"6","key":"10.1016\/j.phrs.2026.108449_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000387","article-title":"BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance","volume":"3","author":"Tarantelli","year":"2018","journal-title":"ESMO Open."},{"key":"10.1016\/j.phrs.2026.108449_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.574525","article-title":"PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc","volume":"10","author":"Li","year":"2020","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108449_bib45","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/jat.2717","article-title":"Epigenetic targets of some toxicologically relevant metals: a review of the literature","volume":"32","author":"Cheng","year":"2012","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.phrs.2026.108449_bib46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2016.03.014","article-title":"Epigenetic modulation by inorganic metal complexes","volume":"319","author":"Leung","year":"2016","journal-title":"Coord. Chem. Rev."},{"issue":"31","key":"10.1016\/j.phrs.2026.108449_bib47","doi-asserted-by":"crossref","first-page":"10160","DOI":"10.1002\/chem.201300814","article-title":"Histone-Deacetylase-Targeted Fluorescent Ruthenium(II) Polypyridyl Complexes as Potent Anticancer Agents","volume":"19","author":"Ye","year":"2013","journal-title":"Chem. Eur. J."},{"key":"10.1016\/j.phrs.2026.108449_bib48","author":"Notaro","year":"2019","journal-title":"Increasing Cytotox. Ru(II) Polypyridyl Complex. Tuning. Electron. Struct. Dioxo Ligands"},{"issue":"1","key":"10.1016\/j.phrs.2026.108449_bib49","doi-asserted-by":"crossref","first-page":"14860","DOI":"10.1038\/ncomms14860","article-title":"Allosteric cross-talk in chromatin can mediate drug-drug synergy","volume":"8","author":"Adhireksan","year":"2017","journal-title":"Nat. Commun."},{"issue":"21","key":"10.1016\/j.phrs.2026.108449_bib50","doi-asserted-by":"crossref","first-page":"10613","DOI":"10.3390\/ijms262110613","article-title":"Combinative Treatment of the PARP Inhibitor Olaparib and Antimetastasis Ruthenium(II)\u2013Arene Compound RAPTA-T for Triple-Negative BRCA1 Wild-Type Breast Cancer Cells","volume":"26","author":"Ratanaphan","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.phrs.2026.108449_bib51","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1002\/chem.201100298","article-title":"A Ruthenium Antimetastasis Agent Forms Specific Histone Protein Adducts in the Nucleosome Core","volume":"17","author":"Wu","year":"2011","journal-title":"Chem. Eur. J."},{"issue":"1","key":"10.1016\/j.phrs.2026.108449_bib52","doi-asserted-by":"crossref","first-page":"43005","DOI":"10.1038\/srep43005","article-title":"Combination of ruthenium(II)-arene complex [Ru(\u03b76-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity","volume":"7","author":"Berndsen","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.phrs.2026.108449_bib53","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1039\/C8MT00024G","article-title":"Metallomic study on the metabolism of RAPTA-C and cisplatin in cell culture medium and its impact on cell accumulation","volume":"10","author":"Holtkamp","year":"2018","journal-title":"Metallomics"},{"issue":"10","key":"10.1016\/j.phrs.2026.108449_bib54","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.3390\/molecules25102383","article-title":"Anticancer Ruthenium Complexes with HDAC Isoform Selectivity","volume":"25","author":"Cross","year":"2020","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.phrs.2026.108449_bib55","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.febslet.2014.02.017","article-title":"Anti-cancer drug KP1019 modulates epigenetics and induces DNA damage response in Saccharomyces cerevisiae","volume":"588","author":"Singh","year":"2014","journal-title":"FEBS Lett."},{"issue":"8","key":"10.1016\/j.phrs.2026.108449_bib56","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1039\/C3SC53243G","article-title":"NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application","volume":"5","author":"Trondl","year":"2014","journal-title":"Chem. Sci."},{"issue":"13","key":"10.1016\/j.phrs.2026.108449_bib57","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.1039\/D4DT00118D","article-title":"Synthesis and preclinical evaluation of BOLD-100 radiolabeled with ruthenium-97 and ruthenium-103","volume":"53","author":"Happl","year":"2024","journal-title":"Dalton Trans."},{"issue":"1","key":"10.1016\/j.phrs.2026.108449_bib58","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1038\/s41598-017-03864-w","article-title":"Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates","volume":"7","author":"Novohradsky","year":"2017","journal-title":"Sci. Rep."},{"issue":"14","key":"10.1016\/j.phrs.2026.108449_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202517286","article-title":"Epigenetic Metal-Organic Framework Nanoagonist Overcomes Triple Defenses to Enable Effective Chemo-Metalloimmunotherapy in Platinum-Resistant Ovarian Cancer","volume":"38","author":"Lin","year":"2026","journal-title":"Adv. Mater."},{"key":"10.1016\/j.phrs.2026.108449_bib60","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jinorgbio.2013.03.011","article-title":"A novel platinum complex of the histone deacetylase inhibitor belinostat: rational design, development and in vitro cytotoxicity","volume":"124","author":"Parker","year":"2013","journal-title":"J. Inorg. Biochem."},{"issue":"44","key":"10.1016\/j.phrs.2026.108449_bib61","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1039\/b916715c","article-title":"A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity","author":"Griffith","year":"2009","journal-title":"Chem. Commun."},{"issue":"10","key":"10.1016\/j.phrs.2026.108449_bib62","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1021\/mp200597r","article-title":"Conjugate of Pt(IV)\u2013Histone Deacetylase Inhibitor as a Prodrug for Cancer Chemotherapy","volume":"9","author":"Yang","year":"2012","journal-title":"Mol. Pharm."},{"issue":"48","key":"10.1016\/j.phrs.2026.108449_bib63","doi-asserted-by":"crossref","first-page":"14478","DOI":"10.1002\/anie.201506533","article-title":"A Photoactivatable Platinum(IV) Complex Targeting Genomic DNA and Histone Deacetylases","volume":"54","author":"Kasparkova","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"issue":"16","key":"10.1016\/j.phrs.2026.108449_bib64","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.3390\/molecules26165010","article-title":"Tributyltin(IV) Butyrate: A Novel Epigenetic Modifier with ER Stress- and Apoptosis-Inducing Properties in Colon Cancer Cells","volume":"26","author":"Giuliano","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2026.108449_bib65","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jinorgbio.2015.06.001","article-title":"Synthesis, chemical characterization, computational studies and biological activity of new DNA methyltransferases (DNMTs) specific inhibitor. Epigenetic regulation as a new and potential approach to cancer therapy","volume":"150","author":"Pellerito","year":"2015","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.phrs.2026.108449_bib66","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.actbio.2022.08.076","article-title":"Copper-olsalazine metal-organic frameworks as a nanocatalyst and epigenetic modulator for efficient inhibition of colorectal cancer growth and metastasis","volume":"152","author":"Li","year":"2022","journal-title":"Acta Biomater."},{"issue":"2","key":"10.1016\/j.phrs.2026.108449_bib67","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s13402-023-00882-x","article-title":"Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer","volume":"47","author":"Finnegan","year":"2024","journal-title":"Cell. Oncol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108449_bib68","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1039\/C5SC02321A","article-title":"An iridium( iii)-based irreversible protein\u2013protein interaction inhibitor of BRD4 as a potent anticancer agent","volume":"6","author":"Zhong","year":"2015","journal-title":"Chem. Sci."},{"issue":"12","key":"10.1016\/j.phrs.2026.108449_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202405771","article-title":"A Bioactive Benzimidazole-Cyclometalated Iridium(III) Complex as an Epigenetic Regulator through Effectively Interrupting the EED\u2013EZH2 Interaction","volume":"21","author":"Cheng","year":"2025","journal-title":"Small"},{"issue":"5","key":"10.1016\/j.phrs.2026.108449_bib70","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1021\/ml100295v","article-title":"Synthesis and Biological Evaluation of JAHAs: Ferrocene-Based Histone Deacetylase Inhibitors","volume":"2","author":"Spencer","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.phrs.2026.108449_bib71","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/cbdv.201200076","article-title":"The [(Cp)M(CO)3] (M=Re,99m Tc) Building Block for Imaging Agents and Bioinorganic Probes: Perspectives and Limitations","volume":"9","author":"Can","year":"2012","journal-title":"Chem. Biodivers."},{"issue":"39","key":"10.1016\/j.phrs.2026.108449_bib72","doi-asserted-by":"crossref","first-page":"8353","DOI":"10.1039\/C5CC02354H","article-title":"A phosphorescent rhenium( i) histone deacetylase inhibitor: mitochondrial targeting and paraptosis induction","volume":"51","author":"Ye","year":"2015","journal-title":"Chem. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108449_bib73","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/0008-5472.CAN-09-3324","article-title":"A Gold(III) Porphyrin Complex with Antitumor Properties Targets the Wnt\/\u03b2-catenin Pathway","volume":"70","author":"Chow","year":"2010","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.phrs.2026.108449_bib74","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2021.07.017","article-title":"Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy","volume":"16","author":"Mikubo","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"14","key":"10.1016\/j.phrs.2026.108449_bib75","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18556","article-title":"Hypomethylation-associated Sox11 upregulation promotes oncogenesis via the PI3K\/AKT pathway in OLP-associated OSCC","volume":"28","author":"Liu","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.phrs.2026.108449_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115559","article-title":"DNA methylation-based depiction of the immune microenvironment and immune-associated long non-coding RNAs in oral cavity squamous cell carcinomas","volume":"167","author":"Calanca","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.phrs.2026.108449_bib77","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3892\/mmr.2024.13421","article-title":"Epigenetic downregulation of the proapoptotic gene HOXA5 in oral squamous cell carcinoma","volume":"31","author":"Chen","year":"2024","journal-title":"Mol. Med. Rep."},{"issue":"2","key":"10.1016\/j.phrs.2026.108449_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.31164","article-title":"Up-regulation of TNF-alpha\/NFkB\/SIRT1 axis drives aggressiveness and cancer stem cells accumulation in chemoresistant oral squamous cell carcinoma","volume":"239","author":"De Castro","year":"2024","journal-title":"J. Cell. Physiol."},{"issue":"21","key":"10.1016\/j.phrs.2026.108449_bib79","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1080\/15384101.2015.1090063","article-title":"The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma","volume":"14","author":"Banelli","year":"2015","journal-title":"Cell. Cycle"},{"key":"10.1016\/j.phrs.2026.108449_bib80","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.omtn.2019.02.010","article-title":"LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K\/AKT Pathway in NSCLC","volume":"16","author":"Liu","year":"2019","journal-title":"Mol. Ther. - Nucleic Acids"},{"issue":"1","key":"10.1016\/j.phrs.2026.108449_bib81","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41375-019-0497-6","article-title":"Loss of KDM6A confers drug resistance in acute myeloid leukemia","volume":"34","author":"Stief","year":"2020","journal-title":"Leukemia"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826003646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826003646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:57:36Z","timestamp":1789901856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826003646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":81,"alternative-id":["S1043661826003646"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108449","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metal-based epigenetic therapeutics in cancer: Mechanisms, targets, and opportunities for overcoming drug resistance","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108449","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108449"}}